BIM.PA - bioMérieux S.A.

Paris - Paris Delayed price. Currency in EUR
77.40
-1.10 (-1.40%)
As of 3:19PM CEST. Market open.
Stock chart is not supported by your current browser
Previous close79.00
Open78.60
Bid114.00 x 36200
Ask115.75 x 25000
Day's range77.30 - 79.10
52-week range59.00 - 82.20
Volume70,030
Avg. volume123,686
Market cap9.141B
Beta0.44
PE ratio (TTM)38.32
EPS (TTM)2.02
Earnings date5 Sep 2018
Forward dividend & yield0.34 (0.42%)
Ex-dividend date2018-06-05
1y target est66.08
  • Should You Sell bioMérieux SA. (EPA:BIM) At This PE Ratio?
    Simply Wall St.5 days ago

    Should You Sell bioMérieux SA. (EPA:BIM) At This PE Ratio?

    bioMérieux SA. (ENXTPA:BIM) trades with a trailing P/E of 40.5x, which is higher than the industry average of 27.8x. While this makes BIM appear like a stock to avoid orRead More...

  • Globe Newswire2 months ago

    Biom’up Finalizes U.S. Commercial Organization to Support U.S. Launch of HEMOBLAST™ Bellows

    SAINT-PRIEST, France, May 02, 2018 (GLOBE NEWSWIRE) -- Biom'up (EPA:BUP), a specialist in surgical hemostasis, today announced it has finalized the commercial infrastructure to support the imminent launch of its lead product HEMOBLAST Bellows. The Company has recruited senior management and a large number of independent specialist sales representatives to drive the nationwide marketing and sales campaign of HEMOBLAST Bellows, which is expected to start in mid-2018. With a large team of specialists now in place, and given its clinically demonstrated high value, we are confident that HEMOBLAST Bellows will make substantial inroads and become a fixture of hemostasis in operating rooms across the USA.

  • Globe Newswire2 months ago

    Biom'up reports 2017 full-year results and provides corporate update

    SAINT-PRIEST, France, April 16, 2018 (GLOBE NEWSWIRE) -- Biom'up (the "Company"), a specialist in surgical hemostasis, today announced its 2017 full-year results, as approved by the Company's Board of Directors on April 13, 2018. Etienne Binant, CEO of Biom'up, said: "2017 was a pivotal year for Biom'up, during which we successfully positioned the Company to become a strong contender in the hemostasis space.

  • Reuters - UK Focus10 months ago

    European stocks bounce back as strong earnings in focus

    Investors piled back into European stocks on Wednesday, boosting indexes higher in a rally a day after geopolitical concern caused a drop across equity markets. The pan-European STOXX 600 gained 0.7 percent, ...

  • Reuters - UK Focus10 months ago

    European stocks bounce back as strong earnings in focus

    Investors piled back into European stocks on Wednesday, boosting indexes higher in a relief rally after geopolitical concerns caused a sharp dip across equity markets. The pan-European STOXX 600 gained ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes